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Abstract. Background/Aim: Primary tumors display a great
level of intra-tumor heterogeneity in breast cancer. The
current lack of prognostic and predictive biomarkers limits
accurate stratification and the ability to predict response to
therapy. The aim of the present study was to select
recombinant antibody fragments specific against breast
cancer subpopulations, aiding the discovery of novel
biomarkers. Materials and Methods: Recombinant antibody
fragments were selected by phage display. A novel
shadowstick technology enabled the direct selection using
tissue sections of antibody fragments specific against small
subpopulations of breast cancer cells. Selections were
performed against a subpopulation of breast cancer cells
expressing CD271+, as these previously have been indicated
to be potential breast cancer stem cells. The selected antibody
fragments were screened by phage ELISA on both breast
cancer and myoepithelial cells. The antibody fragments were
validated and evaluated by immunohistochemistry
experiments. Results: Our study revealed an antibody
fragment, LH8, specific for breast cancer cells. Immuno -
histochemistry results indicate that this particular antibody
fragment binds an antigen that exhibits differential expression
in different breast cancer subpopulations. Conclusion:
Further studies characterizing this antibody fragment, the
subpopulation it binds and the cognate antigen may unearth
novel biomarkers of clinical relevance. 
Today it is widely recognized that breast cancer is a disease
that exhibits a large degree of heterogeneity, between and
within patients. The heterogeneity between patients is
characterized as belonging to one of several histological
subtypes. Within any given patient, heterogeneity exists
between the primary lesion and metastasis. Even within
individual primary tumors different subpopulations of cancer
cells co-exist, each displaying diverse sets of properties. This
well-documented intra-tumor heterogeneity greatly affects
morphology, growth, propensity to form metastasis,
therapeutic resistance and recurrence of the individual tumor
(27). Genetic and epigenetic alterations, stochastic gene
expression and fluctuations in signaling pathways are all
contributing factors to the diversity between different cancer
cells (22, 23, 28). The intra-tumor heterogeneity is also
shaped by extrinsic factors inherent to the microenvironment
in which the tumor resides (25). It has been shown, that
progression of the tumor is influenced by the surrounding
stroma cells, extracellular matrix, paracrine factors or local
conditions such as hypoxia (8, 16, 35). The complex network
of cellular interactions with the microenvironment plays an
important role in the antigens expressed by the cancer cells
and may also influence therapeutic response (13, 26).
Most often, the molecular sub-classification of breast
cancer is based on observation of the expression of a limited
number of prognostic and predictive markers. Among these
the estrogen (ER) and progesterone (PR) hormone receptors
and ERBB2 (HER2) are the ones most commonly used (5).
With the introduction of modern sequencing and DNA-based
technologies, it has been verified that multiple biopsies
obtained from the same tumor may possess genomic
variations (2). Even when considering the established
markers, such as HER2 status, variance has been established
within primary tumors (6, 10). This poses a real clinical
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challenge. A definitive diagnosis can, therefore, be
obstructed by intra-tumor heterogeneity. Furthermore, the
heterogeneity provides undefined subpopulations of breast
cancer cells, often with unknown response to therapy. 
By expanding the number of clinical-relevant biomarkers,
characterization of individual breast cancer subpopulations
will be improved. Furthermore, it will enhance the ability to
accurately stratify breast cancer patients, detect recurring
disease and predict resistance to therapy.
Studies performed on primary tumors, recurrent/metastatic
lesions, circulating tumor cells or breast cancer cultures all
contribute to our understanding of breast cancer as well as
aid in the identification of the “driver” aberrations
responsible for tumor progression and metastasis. The search
for biomarkers has taken numerous approaches involving
genomic, transcriptomic, proteomic or metabolic studies (1,
3, 7, 9, 17, 18, 30, 31). In the present study, we propose to
unearth novel biomarkers through isolation of breast cancer
cell-specific antibody fragments by performing in vitro
selection of antibody libraries directly on tissue sections.
Display technologies such as phage display, is a widely used
method to generate cell-specific recombinant antibody
fragments. It allows for in vitro selection of recombinant
antibody fragments against unknown target antigens
represented in any kind of material, such as cells, tissue or
blood (20, 32, 34). The phage display technology may
generate antibody fragments which cannot be obtained
through in vivo immunization or infection, as the isolation
does not rely on immunogenicity of the antigens, but purely
binding between antibody and antigen (4). Furthermore, this
technology may be capable of detecting differentially
expressed biomarkers (12, 14). Antibody fragments have
proven to be valid alternatives to full-size IgG antibodies,
and their discovery, including the identification of their
corresponding antigens, is highly useful for development of
new diagnostic tools and individualized treatment (11).
Within the pharmaceutical industry, increased attention is
being paid on recombinant antibody technologies (24).
During the past four years 54 biopharmaceutical products
have been approved, out of which 17 were monoclonal
antibodies (37).
Herein, we isolated one antibody fragment, LH8, which in
IHC experiments specifically binds breast cancer cell
subpopulations. We applied a recently established method,
which allows selections to be targeted against small
subpopulations of primary breast cancer cells in tissue (20).
We targeted a particular subpopulation of cancer cells,
capable of both initiating tumors and forming a
differentiation hierarchy, as observed in primary xenografts
after transplantation in NOD SCID gamma mice (15). This
subpopulation of potential breast cancer stem cells is
characterized by the expression of CD271, a marker not
exclusive to cancer cells. The discovery of novel antibody
fragments specifically recognizing biomarkers defining
breast cancer subpopulations has great clinical potential.
Materials and Methods
Tissue sections. Cryostat sections (6-8 μm) from snap-frozen
biopsies of breast cancer patients and healthy donors were prepared
as previously described (29). The use of human material has been
reviewed by the Regional Scientific Ethical Committees for
Copenhagen and Frederiksberg and approved with reference to (KF)
(11) 263995 and for Region Hovedstaden H-2–2011-052 and H-
2–2010-051. Tissue sections used for selections were fixed for 10
min in 3.7% formaldehyde (Sigma-Aldrich Denmark A/S
Copenhagen, Denmark), washed in PBS and incubated twice for 7
mins in 0.01% Triton X-100 (Sigma-Aldrich Denmark A/S
Copenhagen, Denmark). Nuclei were counterstained with
hematoxylin (Sigma-Aldrich). Selections were performed on basal-
like breast cancer tissue from patient 757 with the marker profile:
(ER/PR–/–, cytokeratin (CK)17+, CK5+, low ErbB2, MM+ and
CD271+). Tissue sections used for immunohistochemistry (IHC)
were fixed in ice-cold methanol (Sigma-Aldrich) at –20˚C for 
5 min. Tissue sections from four breast cancer patients were used,
two basal-like breast cancers: P757 and P918 (ER–, CK17+, CK5+,
MM– and CD271+) and two luminal breast cancers: P761 (ER/PR
+/+
, CK17–, CK5+, low ErbB2, MM+ and CD271+) and P686
(ER/PR+/+, CK17–, CK5–, low ErbB2, MM+ and CD271+). 
Target area identification by immunoperoxidase staining with anti-
CD271. Briefly, multiple sections were cut. The middle section was
methanol fixed and used for immunoperoxidase, while the other
sections were formalin fixed, as described. The tissue from the
middle section was encircled with a PAP pen liquid blocker and
blocked for 5 min in Ultra V Block (TA-060-UB, Thermo Scientific,
Roskilde Denmark). The tissue was incubated for 1 h with 50 μL
mouse anti-p75 NGF Receptor antibody (anti-CD271) [ME20.4]
1:50 (Abcam, Cambridge, UK, #ab8877), washed three times with
PBS- (Ca2+ and Mg2+ free). Then incubated with 50 μL Ultravision
ONE HRP Polymer (Thermo Scientific) for 30 min, washed three
times with PBS and finally incubated with 1 mg/mL 3´, 3´-
diaminobenzidine tetrahydrochloride (Dako Denmark A/S, Glostrup,
Denmark) in PBS with freshly added 1 μl/ml of 30% H2O2 (Sigma-
Aldrich) for 10 min. The tissue slide was washed with PBS and
distilled water before the nuclei were counter-stained with
hematoxylin (Sigma-Aldrich). CD271+ cancer cells were found
within a cancer nest in the methanol fixed section. Corresponding
areas were identified on the formalin-sections and used for shadow
stick selection.
Shadow stick. The shadow sticks were fabricated from a pulled
injection microcapillaries (Tritech Research, Inc., Los Angeles,
USA). The metal discs were created by compressing sinter metal
powder, kindly provided by Dansk Sintermetal (Haderslev,
Denmark). The flat pieces of powdered metal were placed on a
microscope slide and attached to the tip of a pulled glass capillary
by drawing up a small volume of epoxy glue into the capillary.
Subsequently, the glue was dispensed on top of a piece of metal
with a desired size. This procedure was done with the capillary
attached to the micromanipulator, to ensure the disc being glued to
the stick in the correct angle. This allows positioning of the disc on
top of the target area using micromanipulation equipment from
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Narishige (Model MM-188, Nikon Denmark, København S,
Denmark). A shadow stick with a diameter of approximately 150
μm was used in this study. 
Shadow stick-selection of antibody fragments using phage display.
The breast cancer tissue sections from P757were formalin-fixed, as
described, and blocked for 1 h in 4% Marvel dried skimmed milk
powder (MPBS) (19). The tissue slide was incubated with the phage
library in a slide container containing 20 ml 2% MPBS overnight
with gentle agitation. The single domain library “predator” was used
which has diversity of 6.2×107 different antibody fragments and a
titer of 1013 pfu/ml with a display level estimated to be 6.4% (21).
Fifty μL phage stock were used per tissue section and incubated
overnight. The slide was washed 10 min in PBS and two times 10
min in PBS with 10% glycerol (PBSG) with gentle agitation. The
slide was dried, except from the target area, which was kept moist
with approximately 10 μL PBSG. Using bright-field microscopy, the
shadow stick was positioned above the target area. The slide was
exposed to UV-C light (254 nm) for 5 min using a UV-C source
(model UVSL-14P from UVP, Upland, CA, USA) positioned on a
stand approximately 4 cm above the slide. Phage particles bound to
the target area was eluted with 15 μL trypsin (1 mg/mL) for 15 min.
Trypsin was aspirated and transferred to a tube before the area was
washed 15 times with 50 μL PBSG, which was transferred to the
eluate as well. For trypsin inactivation 50 μL fetal bovine serum
were added to the eluate before storage at –20˚C. 
Cell cultures. Myoepithelial cells were isolated from trypsinized
organoids derived from normal breast tissue as described previously
(36). Trypsinized cells were incubated with conjugated monoclonal
antibodies NGFR (neurotrophin receptor, p75)/CD271-APC
(ME20.4, 1:50, Cedarlane Laboratories, TriChem Aps, Skanderborg,
Denmark) for 45 min at 4˚C. Then washed 2x in HEPES buffer
supplemented with 0.5% BSA (bovine fraction V; Sigma-Aldrich)
and 2 mM EDTA (Merck) and finally incubated with 1 μg/ml
propidium iodide (Life Technologies) to separate live from dead
cells before analysis and sorting, using a FACSAria I flow
cytometer (BD Biosciences). Sorted cells were set-up in culture on
collagen-coated flasks with BBMYAB medium (publication to
follow). Establishment and culture of the CD271+ subclone from the
BT474 cancer cell line have previously been described (15).
Phage ELISA for screening and titration assay. Phage infection of
E. coli and production of phage antibodies was performed as
described previously (20). Initial screening of potential interesting
phage antibodies was performed on CD271+ cancer cells. Titration
assay was performed simultaneously on both CD271+ cancer cells
and normal CD271+ myoepithelial cells, which enabled the
possibility to reject the phage antibodies binding to common
antigens. As a positive control for the phage ELISA procedure the
phage antibody 52 was used (12). As a negative control, a phage
antibody specific against foetal epsilon-haemoglobin was included
(33). For titration assay, phage antibodies of interest were produced
in 50 ml TG-1 cultures and tested along the above mentioned
controls in a series of six 4-fold serial dilutions, ranging from 1011
phages/well to 9.8×107, as described (20). Phage particles were
quantified by measuring absorbance at 269 nm and 320 nm (21). 
Expression and purification of soluble antibody fragments. To express
the individual clones as soluble antibody fragments, clones were sub-
cloned from the predator phage into a modified pET22b vector
including c-Myc- and His-tag using NcoI and NotI restriction
enzymes (Thermo Scientific) and T4 DNA ligase (Fermentas) before
transformation into BL21 Gold (Agilent Technologies, Glostrup,
Denmark). Expression was initiated with a 4-ml overnight culture in
TB medium containing ampicillin (100 μg/mL) and glucose (4%
w/v). The cultures were diluted 1:100 in 250 ml cultures and grown
until OD600 of 0.6-0.8, then spun for 10 min at 4˚C and 4,000 rpm.
The pellet was re-suspended into TB medium containing ampicillin
(100 μg/ml) and IPTG (100 μg/ml) for induction, and grown 16-18 h
at 30˚C and 200 rpm. The cultures was spun for 1 hour at 5,000 × g
at 4˚C and the antibody fragments in the supernatant was precipitated
with 30% w/v ammonium sulphate by incubation on a roller table at
4˚C overnight. The flasks were spun for 30 min at 5,000 × g at 4˚C
and the pellet re-suspended in 40 ml TBS (pH 8) with approximately
400 U DNase I (Roche) including 5 mM Mg+. The solution was
sterile-filtered with 0.20-μm filters (GF pre-filters) and purified on
HiTrap Protein A HP columns (GE Healthcare A/S, Brøndby,
Denmmark). The fractions containing the antibody fragments were
determined by SDS-PAGE, pooled into a 3.5-kDa MW dialysis tube
(Spectrum Laboratories) and dialysed in 3 l TBS pH 7.5 at 4˚C
overnight with gentle agitation. The dialyzed protein was transferred
to 3-kDa MW VivaSpin columns (GE Healthcare) and spun down to
a concentration of about 1 mg/ml measured on a NanoDrop
spectrophotometer (Thermo Scientific). Purity was verified by SDS-
PAGE and western blotting against c-Myc.
Immunohistochemical staining with soluble domain antibody
fragments. The tissue sections were prepared as described earlier.
The tissue was encircled with a PAP pen and blocked for 1 h with
Ultra V Block (TA-060-UB, Thermo Scientific). Approximately 
25 μg of antibody fragments were dissolved in Ultra V Block, 10%
goat serum and 1:100 anti-CK19 to a total volume of 100 μl, and
added to the encircled area. Incubation was performed for 3 h in
humid chambers. The liquid was removed by aspiration and the
slide washed four times for 1 min in PBS. The slide was incubated
for 30 min in the dark with mouse Cy3 conjugated anti-c-Myc
antibody [9E10] 1:250 (Sigma-Aldrich), Alexa Fluor 488 conjugated
Goat anti-mouse IgG2a 1:500 (Invitrogen, ThermoScientific), DAPI
1:1,000 (Invitrogen) and 10% goat serum dissolved in Ultra V Block
to 100 μL. Alternatively, the antibody fragments above, was
replaced with an anti-Ki67 antibody (Abcam) in a dilution of 1:100
and as secondary antibody a goat anti-rabbit antibody coupled to
Alexa 546 (Thermo Fisher) was added in dilution of 1:500. The
slide was washed three times for 1 min in PBS and mounted with
Flouromount mounting media (Sigma-Aldrich) and cover glass.
Results
Outline. The shadow stick selection procedure on cryostat
tissue sections is based on our previous published work (20).
An outline of the selection and screening approach applied
in this study can be seen in Figure 1. The selections were
performed with a novel single-domain phage antibody library
termed “predator”(21). 
Identifying the target area. Multiple selections were
performed on sections from a single biopsy (P757). This
biopsy had small well-defined tumor cell nests and rare
Larsen et al: Breast Cancer-specific scFv
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Figure 1. Illustration of the antibody fragment selection procedure and screening strategies. The target area for selection was chosen to be the middle
part of a particular cancer nest due to clustered CD271+ staining present. The entire tissue on a consecutive formalin-fixed section was then incubated
with a phage library. The target area was relocated and a minute disc (shadow stick) was positioned precisely above the target cells of interest. The
target area was kept moist at all times. The shadow stick shielded the phage antibodies binding to cells of interest from UV-C irradiation. The phages
were eluted, but only those protected by the shadow stick can replicate in bacteria and provide ampicillin resistance. Each colony represented an
antibody fragment, which required screening for their specificity. They were picked and grown in separate wells of a master plate. 1) In the initial
screening, all colonies were grown in microtiter plates and monoclonal phage antibodies produced. The phage antibodies were tested by phage ELISA
on CD271+ cancer cells. 2) All phage antibodies bound with higher affinities than the negative control in the initial screening were produced
monoclonally in 50-ml cultures. These were tested in different concentrations by a phage ELISA titration assay, which was performed simultaneously
on CD271+ cancer cells and CD271+myoepithelial cells. This provided comparative results of each phage antibody. 3) Soluble antibody fragments
were expressed and purified, and examined by IHC experiments on four different breast cancer biopsies to validate their specificity.
CD271+ staining throughout the tissue. The target area was
chosen to be a high-density cluster of CD271+ cells within
a single cancer nest (Figure 1). The shadow stick shielded
roughly 75-100 cells. The antigens that are presented in
target cells might experience structural changes in the
multiple steps of the CD271 immunostaining. To prevent
this, the selection was performed on separate, but
consecutive non-stained tissue sections. The consecutive
slides used for selection were formalin-fixed and used fresh.
During all steps of the selection procedure, the target area
Larsen et al: Breast Cancer-specific scFv
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Figure 2. Immunohistochemistry showing breast cancer-specific staining with an antibody against fragment LH8. Immunohistochemistry was
performed on three seperate sections of cryostat tissue from the luminal breast cancer patient 761. All pictures are merged with DAPI staining.
Pictures A, C and E show staining against CK19, which indicate the presence of cancer cells. Picture B shows staining with the antibody fragment
LH8 which consistently only binds cancer cells. The presence of cancer cells is confirmed by staining with the proliferation marker ki67 within
these areas, as observed in picture D. Picture F shows staining with the mouse Cy3 conjugated anti-c-Myc antibody used for detection of the
antibody fragments. This shows that the observed staining is not caused by up-regulated c-myc expression in cancer cells or unspecific binding by
this secondary antibody.
was kept moist. The exact corresponding target area was
easily identified on the neighboring slides, by the unique
morphology patterns of the tumor cell nests.
Selection and screening. As the number of phage antibodies
retrieved in a selection varies, multiple selections were
performed in parallel. In the present study13 selections were
performed on cryostat sections from the breast cancer patient
757. In total, 315 clones were screened by phage ELISA on
CD271-expressing cancer cells with phage antibodies
produced in a 96-well format. The phage antibody “Epsilon”
is specific against epsilon-haemoglobin almost exclusively
expressed by fetal erythroblasts (33). This phage antibody
was included as a negative control in the initial ELISA
screening. Phage antibodies which did not give a signal
above the signal obtained from the negative control Epsilon
was discarded from further analysis. The initial ELISA
screen serves the sole purpose of prioritizing clones for
further analysis. In total, 35 clones gave higher absorbance
compared to the negative control Epsilon. The selection
outputs of the predator library were generally of good quality
and sequencing of the individual genes encoding these 35
antibodies of interest revealed no stop-codons, truncations,
frameshift mutations or other abnormalities, as expected. The
35 phage antibodies were produced in 50-ml cultures and
tested by titration phage ELISA in dilution series, as
described. This was performed simultaneously on both
CD271+ cancer cells and CD271+ myoepithelial cells. This
allows for comparison between the individual phage
antibodies and the two cell lines. The phage antibodies that
bound equally well or better to myoepithelial cells were
considered as common-epitope binders and not tested further.
The phage antibody LH8, exhibited preferential binding to
CD271+ cancer cells compared to the CD271+ myoepithelial
cells. Eleven out of the 35 tested phage antibodies were
prioritized for further validation as they bound better to the
CANCER GENOMICS & PROTEOMICS 13: 21-30 (2016)
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Figure 3. Immunohistochemistry showing differential staining intensity in patient 761. The figure shows two different areas on the same section of
a cryostat tissue from the luminal breast cancer patient 761. All pictures are merged with DAPI staining. Pictures A and C show staining against
CK19. Picture B and D shows staining with the antibody fragment LH8. Although the pictures are from the same tissue section there exist variations
in the staining pattern. Cancer cells are not uniformly stained but rather display different areas with different intensity. Some areas of cancer cells
present very limited staining (Figure D, upper left and right) whereas others are very intense. 
CD271+ cancer cells compared to CD271+ myoepithelial
cells. Soluble antibody fragments were expressed and
purified before validation by IHC.
Test of antibody specificity by immunohistochemistry and
ELISA. IHC was performed with 11 soluble antibody
fragments on cryo-preserved breast tissues from biopsies of
four different cancer patients and three healthy donors. All
tissue sections were co-stained with anti-CK19 to distinguish
cancer cells with luminal characteristics from surrounding
stroma. The majority of antibody fragments did not display
cancer-specific staining, whereas the antibody fragment LH8
consistently showed staining restricted within tumor cell
nests (Figure 2). This staining pattern indicated that this
particular antibody fragment binds a cancer-associated
antigen. Furthermore, LH8 stained a majority of cancer cells
but with clear differences in intensity in different regions of
tumor cell nests (Figures 3 and 4), staining was almost
absent in certain cancer areas. This indicates that the antigen,
to which LH8 binds, is expressed differently in different sub-
populations of breast cancer. Apparently, the staining pattern
of this antibody fragment does not distinguish between basal-
like and luminal cancers. It bound cancer cells in all different
cancer biopsies it was tested on (data not shown) and all
displayed higher intensity in certain areas. IHC performed
on breast tissue from three healthy donors did not show any
binding with LH8 (Figure 5). As the staining pattern with
LH8 coincided to some degree with CK19, this antibody
fragment was also tested against coated full length human
CK19 (ab73639) by ELISA. No reactions were observed in
the ELISA experiments (data not shown), while this does not
exclude binding of selected antibodies to CK19 due to other
conformations of the epitopes in tissue, it is indicative of an
alternative antigen being bound. Furthermore, IHC
performed on healthy breast tissue showed no co-staining
with any of the rare CK19-positive cells present. Taken
together these results indicate that the antibody fragment
LH8 binds to an alternate antigen.
Larsen et al: Breast Cancer-specific scFv
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Figure 4. Immunohistochemistry showing differential staining intensity in patient 686. The figure shows two different areas on cryostat tissue from
luminal breast cancer of patient 686 at higher magnification. All pictures are merged with DAPI staining. Pictures A and C show staining against
CK19. Pictures B and D show staining with LH8. The pictures are representative and display an obvious difference in staining intensity in different
cancer areas.
Discussion
The isolation of cancer-specific antibody fragments is an
initial step in the discovery of novel biomarkers for breast
cancer. This article describes an antibody selection procedure
where phage display of antibody fragments is applied on
tissue. The advantage of such selections is that the tumor
microenvironment is preserved and allows for selection of
antibody fragment binding to antigens expressed at very
specific locations within the tumor. The shadow stick shields
phage particles binding to the target area from UV-C
exposure, whereas all phage particle binding to areas outside
the area protected by the shadow stick will experience cross-
linking of their DNA and are, therefore, non-replicable in E.
coli. Generally, this targeted-selection approach yields a low
amount of output clones from each selection, but the
frequency of phage antibodies binding to unique or up-
regulated antigens is relatively high compared to traditional
selections. This is due to the fact that only one round of
selection is performed, thereby preserving diversity of
binders and decreasing the bias toward selection of
antibodies that bind with high affinity to highly expressed
common antigens. 
In the present study, multiple selections were performed
in parallel on sections from a single biopsy. In this biopsy a
cluster of CD271+ cells within a single cancer nest were
targeted for selection. Potentially, these CD271+ cells can be
classified as breast cancer stem cells (15). To preserve the
structural presentation of antigens, the CD271+ target area
was identified on a separate slide, and the selections
performed on consecutive neighbouring sections. As CD271+
cells were targeted for selection on tissue, the screening of
recombinant antibodies were likewise performed on CD271+
breast cancer cells. As CD271+ status is common in
myoepithelial cells surrounding tumor cell nests in the tissue,
these cells were convenient for the purpose of identifying
and discarding common epitope binders, including binders
to the antigen CD271+. Titration assays were performed
CANCER GENOMICS & PROTEOMICS 13: 21-30 (2016)
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Figure 5. Immunohistochemistry performed on healthy breast tissue. For further characterization of LH8, immunohistochemistry was performed on
tissue sections from three healthy donors. Picture A, D and G show DAPI staining. B, E and H show staining against CK19. Picture C, F and I
show staining with the antibody fragment LH8. The upper, middle and lower rows represent the healthy donors P671, P820 and P923 respectively.
No staining was observed in neither the healthy luminal cells or stroma. 
simultaneously on both CD271+ cancer cells and CD271+
myoepithelial cells and it was the binding difference between
the two cell types that was of interest. 
The selected antibody fragment LH8 repeatedly displayed
cancer-specific binding by IHC. Furthermore, this binding
showed a great degree of variability in different areas of the
tumor, indicating that the antigen being recognized by the
antibody fragment is expressed differently by the various
breast cancer subpopulations (Figures 2-4). No particular
staining was observed in the surrounding stroma nor in breast
tissue sections from healthy donors (Figure 5). The
identification and validation of the cognate antigen is often a
challenging and time-consuming task, but will provide
significant knowledge to cancer biology. Typically, this would
be performed by mass spectrometry analysis or screening of
commercial protein micro-arrays or cDNA expression
libraries. The chemical nature of the epitope to which the
antibody fragment LH8 binds could range from being a linear
polypeptide epitope to a conformational epitope or include
post-translational modifications, such as glycosylation.
New biomarkers and therapeutic reagents are urgently
required to improve breast cancer patient stratification and
targeted therapy. While traditional genomics and proteomics
strategies have provided and will continue to provide such
biomarkers, we have taken an alternative approach relying on
the selections of recombinant antibody fragments on tissue
using phage display and shadow stick technology. This
technology allows selection of recombinant antibody
fragments specific for any kind of antigen presented by rare
cells mixed within a heterogeneous population. The selected
antibody fragment LH8 showed differential staining intensity
in different areas within tumor cell nests and did not show
staining of normal breast tissue. This indicates that the cognate
antigen is differentially expressed or post-translationally
modified in different subpopulations of breast cancer cells.
Future characterization of these breast cancer subpopulations
and identification of the cognate antigen may provide new
insight of clinical relevance and aid in the development of new
strategies for diagnosis and targeted therapy.
Conflicts of Interest 
The Authors declare that they have no conflicts of interests.
Acknowledgements
The Authors thank Benedikte Thuesen, Københavns Privathospital
and the donors for providing any normal breast biopsy material, and
Vera Timmermans Wielenga, Pathology Department, Rigshospitalet
for confirming the normalcy of the tissue and providing any cancer
tissue. 
The work was supported by Novo Nordisk Foundation (to
DANSTEM), and Danish Research Council (to DANSTEM) (grant
number 10-092798). The Danish Council for Research and
Innovation (to PK) (grant number 09-069982) and the Danish
Council for Independent Research Technology and Production
Sciences to (PK) and the Sino-Danish center to (SL) (grant number
12–126975).
References
1 Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson
L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL,
Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P,
Parekh R and Terrett JA: Comprehensive proteomic analysis of
breast cancer cell membranes reveals unique proteins with
potential roles in clinical cancer. J Biol Chem 278: 6482-6489,
2003.
2 Benetkiewicz M, Piotrowski A, Diaz De Stahl T, Jankowski M,
Bala D, Hoffman J, Srutek E, Laskowski R, Zegarski W and
Dumanski JP: Chromosome 22 array-CGH profiling of breast
cancer delimited minimal common regions of genomic
imbalances and revealed frequent intra-tumoral genetic
heterogeneity. Int J Oncol 29: 935-945, 2006.
3 Bullinger D, Neubauer H, Fehm T, Laufer S, Gleiter CH and
Kammerer B: Metabolic signature of breast cancer cell line
MCF-7: profiling of modified nucleosides via LC-IT MS
coupling. BMC biochem 8: 25, 2007.
4 Chan CE, Lim AP, MacAry PA and Hanson BJ: The role of
phage display in therapeutic antibody discovery. Int Immunol
2014.
5 Correa Geyer F and Reis-Filho JS: Microarray-based gene
expression profiling as a clinical tool for breast cancer
management: are we there yet? Int J Surg Pathol 17: 285-302,
2009.
6 Cottu PH, Asselah J, Lae M, Pierga JY, Dieras V, Mignot L,
Sigal-Zafrani B and Vincent-Salomon A: Intratumoral
heterogeneity of HER2/neu expression and its consequences for
the management of advanced breast cancer. Ann Oncol 19: 595-
597, 2008.
7 Dawson SJ, Rueda OM, Aparicio S and Caldas C: A new
genome-driven integrated classification of breast cancer and its
implications. EMBO J 32: 617-628, 2013.
8 Egeblad M, Nakasone ES and Werb Z: Tumors as organs:
complex tissues that interface with the entire organism. Dev Cell
18: 884-901, 2010.
9 Goncalves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron
Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel
G, Chabannon C, Extra JM, Viens P, Borg JP and Birnbaum D:
Protein profiling of human breast tumor cells identifies novel
biomarkers associated with molecular subtypes. Mol Cell
Proteomics 7: 1420-1433, 2008.
10 Hanna W, Nofech-Mozes S and Kahn HJ: Intratumoral
heterogeneity of HER2/neu in breast cancer – a rare event.
Breast J 13: 122-129, 2007.
11 Holliger P and Hudson PJ: Engineered antibody fragments and
the rise of single domains. Nat Biotechnol 23: 1126-1136, 2005.
12 Jensen KB, Jensen ON, Ravn P, Clark BF and Kristensen P:
Identification of keratinocyte-specific markers using phage
display and mass spectrometry. Mol Cell Proteomics 2: 61-69,
2003.
13 Junttila MR and de Sauvage FJ: Influence of tumour micro-
environment heterogeneity on therapeutic response. Nature 501:
346-354, 2013.
Larsen et al: Breast Cancer-specific scFv
29
14 Kierny MR, Cunningham TD and Kay BK: Detection of
biomarkers using recombinant antibodies coupled to
nanostructured platforms. Nano Rev 32012.
15 Kim J, Villadsen R, Sorlie T, Fogh L, Gronlund SZ,
Fridriksdottir AJ, Kuhn I, Rank F, Wielenga VT, Solvang H,
Edwards PA, Borresen-Dale AL, Ronnov-Jessen L, Bissell MJ
and Petersen OW: Tumor initiating but differentiated luminal-
like breast cancer cells are highly invasive in the absence of
basal-like activity. Proc Natl Acad Sci USA 109: 6124-6129,
2012.
16 Knowles HJ and Harris AL: Hypoxia and oxidative stress in
breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res
3: 318-322, 2001.
17 Kodahl AR, Zeuthen P, Binder H, Knoop AS and Ditzel HJ:
Alterations in circulating miRNA levels following early-stage
estrogen receptor-positive breast cancer resection in post-
menopausal women. PloS one 9: e101950, 2014.
18 Kulasingam V and Diamandis EP: Proteomics analysis of
conditioned media from three breast cancer cell lines: a mine for
biomarkers and therapeutic targets. Mol Cell Proteomics 6:
1997-2011, 2007.
19 Larsen SA, Meldgaard T, Fridriksdottir AJ, Lykkemark S,
Poulsen PC, Overgaard LF, Petersen HB, Petersen OW and
Kristensen P: Selection of a breast cancer subpopulation-specific
antibody using phage display on tissue sections. Immunol Res
62: 263-272, 2015.
20 Larsen SA, Meldgaard T, Lykkemark S, Mandrup OA and
Kristensen P: Selection of cell-type specific antibodies on tissue-
sections using phage display. J Cell Mol Med 19: 1939-1948,
2015.
21 Mandrup OA, Friis NA, Lykkemark S, Just J and Kristensen P:
A novel heavy domain antibody library with functionally
optimized complementarity determining regions. PloS one 8:
e76834, 2013.
22 Marusyk A, Almendro V and Polyak K: Intra-tumour
heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:
323-334, 2012.
23 Marusyk A and Polyak K: Tumor heterogeneity: causes and
consequences. Biochim Biophys Acta 1805: 105-117, 2010.
24 Nelson AL, Dhimolea E and Reichert JM: Development trends
for human monoclonal antibody therapeutics. Nat Rev Drug
Discov 9: 767-774, 2010.
25 Park CC, Bissell MJ and Barcellos-Hoff MH: The influence of
the microenvironment on the malignant phenotype. Mol Med
Today 6: 324-329, 2000.
26 Pietras K and Ostman A: Hallmarks of cancer: interactions with
the tumor stroma. Exp Cell Res 316: 1324-1331, 2010.
27 Polyak K: Heterogeneity in breast cancer. J Clin Invest 121:
3786-3788, 2011.
28 Raj A and van Oudenaarden A: Nature, nurture, or chance:
stochastic gene expression and its consequences. Cell 135: 216-
226, 2008.
29 Ronnov-Jessen L and Petersen OW: Induction of alpha-smooth
muscle actin by transforming growth factor-beta 1 in quiescent
human breast gland fibroblasts. Implications for myofibroblast
generation in breast neoplasia. Lab Invest 68: 696-707, 1993.
30 Russnes HG, Navin N, Hicks J and Borresen-Dale AL: Insight
into the heterogeneity of breast cancer through next-generation
sequencing. J Clin Invest 121: 3810-3818, 2011.
31 Samuel N and Hudson TJ: Translating genomics to the clinic:
implications of cancer heterogeneity. Clin Chem 59: 127-137,
2013.
32 Sorensen MD, Agerholm IE, Christensen B, Kolvraa S and
Kristensen P: Microselection--affinity selecting antibodies
against a single rare cell in a heterogeneous population. J Cell
Mol Med 14: 1953-1961, 2010.
33 Sorensen MD, Gonzalez Dosal R, Jensen KB, Christensen B,
Kolvraa S, Jensen UB and Kristensen P: Epsilon haemoglobin
specific antibodies with applications in noninvasive prenatal
diagnosis. J Biomed Biotechnol 2009: 659219, 2009.
34 Sorensen MD, Melchjorsen CJ, Mandrup OA and Kristensen P:
Raising antibodies against circulating foetal cells from maternal
peripheral blood. Prenat Diagn 33: 284-291, 2013.
35 Tlsty TD and Coussens LM: Tumor stroma and regulation of
cancer development. Annu Rev Pathol 1: 119-150, 2006.
36 Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T,
Rank F, LaBarge MA, Bissell MJ and Petersen OW: Evidence
for a stem cell hierarchy in the adult human breast. J Cell Biol
177: 87-101, 2007.
37 Walsh G: Biopharmaceutical benchmarks 2014. Nat Biotechnol
32: 992-1000, 2014.
Received September 5, 2015
Revised October 5, 2015
Accepted October 26, 2015
CANCER GENOMICS & PROTEOMICS 13: 21-30 (2016)
30
